seo-company

Maurizio Voi

Vice President, Global Program Head, Tislelizumab, Immuno Oncology at Novartis

I am currently Vice President, Global Program Head, Tislelizumab, Immuno Oncology at Novartis. I was previously Executive Vice President, Chief Medical and Development Officer at Curis. I was responsible for all the Research & Development activities ranging from early drug discovery, to filing IND's on new drugs moving into clinical development to the conduction of clinical studies with drugs already in the clinic. I was also in charge of the Business Development activities related to asset acquisitions. Previously, I was Vice President in the Clinical Development and Medical Affairs organization for the Oncology Business Unit at Pfizer’s Global Research and Development site in New York, NY. I joined Pfizer in 2009 as Thoracic Tumor Strategy Team Leader for Oncology. In that role, I was responsible for developing strategic plans for the development of compounds within the Pfizer portfolio for the treatment of thoracic cancers. I possess more than 20 years of a wide-ranging drug development experience. At Eli Lilly, I was involved in preparing the registration dossier for the filing in Non-Small Cell Lung cancer (NSCLC) of Gemzar® in Europe, and later I moved to Lilly US headquarters where I assumed responsibility for Gemzar® worldwide development and commercialization. At Bristol-Myers Squibb (BMS), I was based at its European headquarters where I assumed the roles of Director of Clinical Research, Europe, and then Executive Director, International Medical Organization, Europe. I later moved back to the US where I lead the development and approval of Sprycel® in Chronic Myelogenous Leukemia. More recently, as Executive Director, Global Medical Affairs, Oncology, BMS, I lead the development of Erbitux® in colo-rectal, NSCLC and head and neck cancer. I have published more than 20 articles, primarily in the areas of early stage drug development, and NSCLC. I received my M.D. from the University of Padua, School of Medicine Italy in 1985.

Contact Information

Business Email
m*****@novartis.com
Personal Email
m*****@yahoo.com
Direct Phone
+1 20********
Location
United States

Company Information

Company
Headquarters
Founded Year
1996
Headcount
Over 10,000 ( View All )
Specialties
ResearchInnovationQualitySustainabilityinnovative medicinesgeneric medicines and biosimilarsglobal leader in eye careunique portfolio focuses & broad healthcare portfolioCell & Gene TherapyData & Digital

Similar Profiles

Profiles With a Similar Industry
Augusto Geraldi

Business Director Pharmaceutical Systems - Latam and Brazil

Marcos Inocencio

Chief Financial Officer - CFO & Chief People Officer -CPO / CHRO

Simon Li

General Manager, China

Sean Low

Director, Worldwide Late Life Cycle Management

Nishant Kumar

Assistant General Manager Information Technology

Other People Whose First Name Is Maurizio
Maurizio Brandolini

senior test driver of tires and vehicles end simulator

Maurizio Maccari

Global Account Director Telecom Italia

Other People Whose Last Name Is Voi
Rodrigo Teixeira Voi

Coordenador de qualidade

Mathias Voi

Manager Fixed Asset & Property

Anthony Voi

Project Engineer

Start with AroundDeal For Free!

Instant access. Cancel anytime

Sign Up to View Maurizio Voi’s Contact Info

Instant access. Cancel anytime

View Colleagues

Maria Borisova
Maria Borisova

Head of Strategic Projects

Andrey L.
Andrey L.

Senior Principal Software Engineer, Technical Lead

Andres Graziosi
Andres Graziosi

Global Head Pharma Strategy and Commercial Execution

Barbara Taylor
Barbara Taylor

NHS Partnership, Communications and Patient Engagement Lead

Frequently Asked Questions Regarding Maurizio Voi

What company does Maurizio Voi work for?
Maurizio Voi works for Novartis
What is Maurizio Voi’s role in Novartis?

Maurizio Voi's role in Novartis is Vice President, Global Program Head, Tislelizumab, Immuno Oncology

Who are Maurizio Voi’s colleagues?

Maurizio Voi's colleagues are Maria Borisova, Andrey L., Andres Graziosi, Barbara Taylor.